Iranian scientists have developed a radiopharmaceutical for targeted treatment of neuroendocrine tumors, in another great step in the country’s efforts to use nuclear technology to promote medical science.
Rhenium-188 can be used in treating cancer developing neuroendocrine cells that have characteristics similar to nerve cells and hormone-producing cells.
Neuroendocrine tumors are rare and can develop anywhere in the body.
Most of the tumors arise in the lungs, appendix, small intestine, rectum, and pancreas.
Using the radiopharmaceutical, it is possible to diagnose and the treatment of neuroendocrine tumors and the resulting metastases will be provided to patients in the early stages of the disease.
Western European leaders are exploring the possibility of deploying troops to Ukraine as part of…
EU leaders could not reach an agreement on what security guarantees they can offer Ukraine…
Iranian Foreign Ministry spokesman Esmaeil Baqaei stated that following the fall of Daesh terror group,…
At least 68 percent of Israelis who took part in a poll did not think…
A renowned Iranian scholar of law, who has been in headlines in recent years for…
A former Iranian diplomat has proposed naming a street in the Iranian capital Tehran after…